Tuberculosis (TB) is the leading cause of mortality in people living with HIV (PLHIV).1,2 Among 10.4 million new TB cases in 2015, HIV codisease was highest in sub-Saharan Africa.2 Key populations including female sex workers (FSWs) have a high HIV prevalence,3 placing them at increased risk for TB.4,5
Isoniazid preventive therapy (IPT) decreases risk of progression from latent TB infection (LTBI) to active TB,6–8 and IPT provision to high-risk groups is a cornerstone of the World Health Organization (WHO) End TB Strategy.9,10 Despite WHO recommendations,7 there has been limited global uptake of this intervention.2 Similar to the HIV care continuum,11 successful IPT implementation requires completion of several steps.12 The optimal approach for IPT delivery is unknown, and few published reports examine this cascade of care in high TB/HIV burden settings,13,14 or within key populations including FSWs.15–18
Kenya is one of the top 20 high TB/HIV burden countries, with TB incidence of 233/100,000,2 and over a third of TB cases occurring in PLHIV.19 In 2014, Kenya guidelines included a strong recommendation for IPT provision to PLHIV.20 However, only 33% of patients newly enrolled in HIV care initiated IPT in 2015.2
Assessment of the IPT care cascade is useful to inform national roll-outs in Kenya and other high TB/HIV burden countries. Challenges to IPT provision may vary by population. Data from general and key populations are important for program planning and implementation. Our objective was to characterize the cascade of IPT delivery, including reasons for cascade losses, among HIV-positive FSWs enrolled in a research cohort in Mombasa, Kenya, which began providing IPT as part of routine HIV care in 2000.
Study Setting and Participants
We abstracted data from clinical care records from a prospective research cohort of HIV-positive FSWs followed at the Ganjoni Clinic in Mombasa, Kenya (the Mombasa Cohort), between March 2000 and January 2010. The Mombasa Cohort was established in 1993 to investigate HIV incidence and risk factors among FSWs.3 Additional detailed Mombasa Cohort description and procedures have been published.21,22
IPT Provision and Routine HIV Care
In 2000, the program initiated IPT as part of routine HIV care because of growing evidence of IPT benefit for TB prevention in PLHIV.23,24 Routine IPT was not provided in Kenya at the time, and Kenyan guidelines recommended limiting IPT to controlled settings where thorough screening and follow-up for potential side effects could be ensured, without specific recommendations for chest radiograph (CXR) screening or concomitant ART use.25 The 2000 WHO IPT guidelines did not include recommendations for those with history of TB or during pregnancy.24 Therefore, the program did not provide IPT to women with a history of TB, current pregnancy, or irregular clinic attendance, and included CXR as part of the screening process for IPT. In 2004, the site became one of the first in Kenya to provide antiretroviral therapy (ART) to participants with CD4 lymphocyte counts <200 cells per microliter or AIDS-defining illness, following WHO and Kenya guidelines.22 ART initiation (in eligible women) was then prioritized over IPT because of concerns about pill burden and potential toxicity leading to possible poor adherence in during the initial rollout of ART. In 2005, Kenyan ART guidelines were modified to include individuals with Stage III disease and CD4 lymphocyte counts <350 cells per microliter, which was incorporated into cohort procedures.21
IPT Program Procedures and Cascade of Care
For women eligible for IPT screening, the care cascade comprised of several steps (Fig. 1). First, women underwent TB symptom screening (presence of cough >2 weeks, fever >2 weeks, unintentional weight loss >2 kg, night sweats, shortness of breath, or pleuritic chest pain). Women with positive symptom screens were referred to the Ministry of Health TB clinic within the facility for further workup (Supplemental Digital Content, Figure 1, http://links.lww.com/QAI/B44). Patients were screened for TB symptoms at follow-up visits; however, data regarding subsequent symptom screening were not routinely recorded for the purpose of this study.
TB diagnosis included sputum smear evaluation and a clinical algorithm for identifying patients with smear-negative TB based on continued symptoms, CXR abnormality, and lack of response to antibiotics for typical causes of pneumonia.25 Women with initially positive symptom screens could continue IPT cascade procedures once TB workup was negative. Those with negative symptom screens (or negative TB workup for initially positive screens) were referred for counseling regarding IPT to reduce risk of active TB, cough hygiene/ventilation to prevent TB exposure, adherence counseling, potential side effects, and refill procedures. After counseling, women were referred for CXR. Those with abnormal CXR were referred to the Ministry of Health TB clinic for further evaluation.
Women with negative symptom screen and CXR (or negative TB work-up) were offered a 6-month course of IPT.24 Initial medication supply was dispensed by nurses. Isoniazid was coadministered with pyridoxine to reduce neuropathy risk. Refills were provided at 1-month to 3-month intervals, during scheduled HIV care visits. Tuberculosis screening (including CXR), IPT, and pyridoxine were provided at no cost, and women received reimbursement for transport (approximately 100–200 Kenyan shillings) for study visits. Testing for latent TB infection (tuberculin skin test (TST) or interferon gamma-release assay) was not performed based on WHO and Kenyan guidelines.25
At each step, women could appropriately exit, successfully proceed to the next step, or be considered cascade losses. Cascade success required completion of 6 months of IPT within a 9-month period.
Clinic-Level Interventions to Improve IPT Delivery and Documentation
Beginning in March 2000, initiation and completion of IPT were documented in clinical notes within participants' research files and an IPT register. In July 2000, an “IPT stamp” was created to mark the front cover of participants' files to record IPT initiation and completion dates. In December 2004, an IPT/TB screening form was added to support efficient and consistent TB symptom screening before IPT initiation.
Data Collection Procedures
Retrospective chart review was performed by study staff using a standardized data collection form. Baseline characteristics, progress through IPT cascade, and reasons for appropriate cascade exit or losses were noted.
For the primary analysis, women were categorized as (1) successfully completed, (2) appropriately exited, or as (3) cascade losses (Fig. 1). Women were considered to have appropriately exited the cascade if they became pregnant, were diagnosed with active TB before initiating and/or during IPT, were ART eligible (once available at the site), had irregular clinic attendance that would likely compromise close follow-up, or IPT discontinuation because of medication intolerance. Cascade losses included all losses along the cascade that did not fit appropriate exit criteria, including loss to follow-up, or unknown/missing reason for exit. The proportion of women who successfully completed, appropriately exited, or were considered cascade losses were calculated for each step and cumulatively. Correlates of cascade losses were identified by comparing baseline characteristics of FSWs with cascade success vs. cascade losses.
Categorical baseline characteristics were summarized by frequency and proportion, and by median and interquartile range (IQR) for continuous variables. Bivariable logistic regression was used to assess associations between potential correlates and the outcome of cascade loss using unadjusted odds ratios (ORs). Adjusted odds ratios (AORs) were calculated using multivariable logistic regression models adjusted for variables associated with cascade losses in unadjusted analyses (P ≤ 0.10). Odds ratio estimates were reported with 95% confidence intervals (CI). STATA version 12.0 (StataCorp, College Station, TX) was used for all statistical analysis.
Because WHO and Kenyan IPT eligibility criteria during the study period differ from current guidelines, we performed additional analyses to assess whether our primary results were sensitive to differences in appropriate cascade exit definitions. After reclassifying individuals not offered IPT because of irregular clinic attendance, participant refusal, ART eligibility, or pregnancy as cascade losses, we repeated analyses calculating overall cascade losses and appropriate exits and correlates of cascade loss.
This study was approved by the Kenyatta National Hospital-University of Nairobi Ethics and Research Committee, the University of Washington Human Subjects Research Committee, and the Fred Hutchinson Cancer Research Center's Institutional Review Board.
Between March 2000 and January 2010, 846 HIV-positive FSWs were seen for at least one Mombasa Cohort study visit. Of these, 204 (24%) were considered ineligible for IPT evaluation. Ineligible women included 106 (13%) with history of active TB, 80 (39%) lost to follow-up before staff could initiate IPT evaluation (typically, immediately after Mombasa Cohort enrollment), and 18 (4%) who were ART-eligible at enrollment (Supplemental Digital Content, Figure 1, http://links.lww.com/QAI/B44). The remaining 642 women were considered eligible for IPT evaluation and are the basis for the remainder of analyses (Fig. 2). Baseline median age was 31 years (IQR 26-35) with median CD4 lymphocyte count of 409 (IQR 292–604) cells per microliter (Table 1). The majority of women were widowed or divorced (421, 66%). Sixty-three (10%) smoked tobacco, 519 (81%) reported alcohol use, and 77 (12%) reported drug use (marijuana, khat, or both). One woman reported injection drug use.
IPT Care Cascade
Of 642 women eligible for IPT evaluation, 517 (80%) completed TB symptom screening, 486 (76%) completed IPT counseling, 375 (58%) completed CXR, and 351 (55%) initiated IPT (Fig. 3). Of 351 women who initiated IPT, 249 (71%) completed a 6-month course, 71 (20%) were lost to follow-up or left the cascade for unknown reasons, and 31 (9%) appropriately discontinued IPT. Figure 2 details the stepwise attrition of participants, including proportion of women evaluable at each step, and reasons for cascade losses or appropriate exit. Sixteen (5%) women discontinued IPT because of medication intolerance, and one developed TB while on IPT (0.003%) (Supplemental Digital Content, Table 1, http://links.lww.com/QAI/B44).
Overall, of the 642 women who entered the IPT care cascade, 249 (39%) successfully completed a 6-month course of IPT, 236 (37%) were considered cascade losses, and 157 (24%) exited the cascade appropriately (Fig. 3). The greatest cascade drop-offs occurred at initial symptom screen, where 90 (14%) participants were reported as cascade losses, and at CXR completion, where an additional 64 (10%) participants from the previous step failed to progress. Among 157 women with appropriate cascade exit, the most common reasons included participant refusal of IPT (49, 31%) or identification of active TB before IPT initiation (34, 22%) (Supplemental Digital Content, Table 1, http://links.lww.com/QAI/B44). For 236 women considered as cascade losses, the majority were lost to follow-up (208, 88%), whereas the remaining (28, 12%) exited the cascade for unknown/missing reasons.
We compared baseline characteristics of women identified as cascade losses to those with successful cascade completion. There was a progressive stepwise increased risk of cascade loss with younger age compared with women >35 years [25-35 years: OR 1.65 (95% CI: 1.06 to 2.56), P = 0.03; <25 years: OR 2.39 (95% CI: 1.34 to 4.26), P = 0.003] (Table 2). Women eligible for IPT evaluation from 2004 onwards (when ART became available) were more likely to have cascade loss [OR 1.78 (95% CI: 1.23 to 2.56), P = 0.002]. Among women with CD4 lymphocyte counts ≥200 cells per cubic millimeter, there was also a trend for cascade loss [OR 1.85 (95% CI: 0.96 to 3.55), P = 0.07]. In multivariate analysis, after adjusting for age, CD4 lymphocyte count, and year of IPT eligible evaluation, younger women and participants eligible for IPT evaluation after 2004 remained at significantly higher risk of cascade loss. Results were similar and remained statistically significant when repeating the analysis with year of IPT eligible evaluation treated as a continuous variable (data not shown).
In our sensitivity analyses, women who were initially considered to have appropriately exited because of irregular clinic attendance, refusal to continue in the cascade, or not offered IPT because of ART eligibility or pregnancy were reclassified as cascade losses.12 This increased cascade losses from 236 (37%) to 336 (52%), whereas reducing appropriate cascade exits from 157 (24%) to 57 (9%). However, the correlates of cascade loss based on these revised definitions resulted in similar or stronger statistically significant associations with younger age and year eligible for IPT evaluation after 2004 (when ART became available (data not shown).
To our knowledge, this is the first study to address the IPT care cascade in HIV-positive African FSWs. Overall, 39% successfully completed IPT, 24% appropriately exited the cascade, and 37% were considered cascade losses. Among those initiating IPT, 6-month completion rates were 71%. The burden of TB was high, with six percent of women diagnosed with active TB before IPT initiation. Only one woman developed TB after starting IPT. Younger age and undergoing IPT evaluation after availability of ART were associated with greater risk of cascade loss.
Program-based exclusion criteria and CXR screening of women without TB symptoms likely contributed to cascade losses. Program decisions regarding exclusion criteria were based on country-specific guidelines at the time, and the lack of data regarding IPT safety, efficacy, and feasibility during pregnancy, in patients with previous TB, and in patients concurrently initiating and continuing ART. Provision of IPT began in this program in 2000, 10 years before release of the 2010 WHO guidelines for intensified TB case-finding and IPT for PLHIV in resource-constrained settings.7 Before 2011, routine IPT for PLHIV in Kenya was recommended only in controlled settings like the research clinic supporting the Mombasa Cohort.25 In 2011, Kenyan HIV care guidelines recommended IPT for PLHIV (including pregnant women and those on ART) in whom active TB had been excluded.26 The 2014 Kenyan HIV care guidelines have since expanded eligibility to include those with previous TB, with IPT initiation recommended at any time after successful TB treatment completion.20 Current WHO guidelines do not require or recommend CXR as part of the routine assessment for IPT eligibility. Elimination of CXR requirement and more inclusive eligibility criteria (including during pregnancy and concurrent ART) would likely increase the number of women receiving IPT. Other barriers, such as individual preference for not initiating IPT and loss to follow-up, are likely to remain relevant under more inclusive contemporary guidelines. In our study, IPT cascade failure was associated with younger age and IPT evaluation eligibility after the availability of ART. Younger age has been associated with lower rates of retention in the HIV care cascade,27–30 and factors impacting HIV care cascade retention likely play a role in TB screening and prevention care cascades. Younger PLHIV may be less likely to perceive their risk for TB and be less willing to take a medication for prevention (like IPT) as opposed to treatment a symptomatic illness. Interventions targeting those at highest risk of loss to follow-up before IPT initiation may strengthen IPT programs. The high proportion of participant refusal of IPT represents an opportunity for improved education and counseling regarding the benefits of IPT to prevent active TB, and remains an important contributor to cascade failure currently. Healthcare provider promotion of IPT and close follow-up to ensure completion of cascade steps, and patient acceptance of IPT may be higher now that this intervention has been more widely promoted and implemented. Latent TB infection status assessment was not performed (ie, TST or interferon gamma-release assay); however, current WHO and Kenyan guidelines recommend IPT be offered to all PLHIV even when TST is not feasible in programmatic settings.7,25 Notably, in the context of the IPT cascade, adding a step could potentially create an additional bottleneck, decreasing the proportion of women successfully completing treatment and will be an important area for future implementation research. To increase comparability of our findings to conditions found under contemporary IPT guidelines, we performed sensitivity analyses reclassifying women who were considered to have appropriately exited the cascade during the time under evaluation as cascade losses under current recommendations. Although cascade losses increased, correlates of cascade losses remained similar.
Strengths of this study include a focus on a key population for which IPT implementation data are lacking, large sample size and longitudinal follow-up, and detailed assessment of reasons for cascade losses at each step. Although FSWs are considered a key population with regard to HIV, there are few studies evaluating IPT provision in this population at risk for TB.15–18 The Global Plan to End TB 2016–2020 has called for a similar 90-90-90 approach inspired by UNAIDS goals for HIV testing, treatment, and viral suppression coverage.31 The plan includes preventive treatment for persons at high risk for TB (including PLHIV), focuses on key populations with increased exposure to TB (including sex workers), and highlights the importance of operational research.31 Available data regarding FSW and the HIV care continuum primarily from research settings suggest that once engaged in HIV care, FSWs can achieve high levels of ART uptake, retention, adherence, and HIV viral suppression.32 The long period of cohort follow-up (10 years) with accrual of over 650 participants eligible to enter the IPT care cascade provided power to detect significant differences in baseline characteristics associated with cascade failure. Detailed assessment of clinical records allowed us to determine individual-level outcomes, including reasons for cascade losses at each step. Prior studies of IPT implementation have primarily focused on completion of IPT among those who initiate therapy, rather than all potentially eligible patients.33,34 By evaluating the entire IPT care cascade, we demonstrated that the majority of cascade losses occur before IPT initiation.
A major strength of the IPT program was the identification of 41/646 (6%) women with active TB before IPT initiation, allowing for appropriate referral to TB care and implementation of measures to reduce transmission risk to staff and other clinic attendees. Notably, 71% of FSWs who initiated IPT in our clinic completed their 6-month course. This is considerably higher than the estimate of 52% in other low-income or middle-income settings reported in a recent systematic review.12 Importantly, there were very few discontinuations because of medication intolerance (<5%) or development of active TB (1 case) while on IPT. Our study adds to the growing body of literature that although provider concerns regarding potential medication intolerance and development of isoniazid-resistant TB on IPT are noted barriers to IPT implementation,12 they remain relatively rare events.
This study had limitations. Data were collected through a retrospective review of clinical data recorded in research participant files within the Mombasa Cohort established to explore the incidence, correlates, prevention, and treatment of HIV and sexually transmitted infections in FSWs, and not originally designed to study IPT implementation. However, IPT provision was added in 2000 as a nonresearch component of HIV care, and this analysis of IPT implementation may be generalizable to routine HIV care settings. Nonetheless, we recognize that the research clinic is likely to have more staff per participant than a typical HIV care setting. Most women were characterized as lost to follow-up if it was clear that they did not continue in the cascade or unknown if no reason was recorded. As such, it is difficult to discern participant-versus clinic-level reasons for cascade losses. Our analysis of reasons for cascade losses was limited to quantitative evaluation of baseline participant characteristics. Systematic reviews of both quantitative and qualitative data have identified individual-level characteristics and beliefs, and interpersonal and structural factors associated with IPT adherence.12,35 In addition, systematic reviews specific to FSW populations have identified substance use, food insecurity, and treatment knowledge and attitudes as factors that influence linkage and retention in HIV care,36 and likely impact IPT uptake as well. Although adherence counseling was performed at follow-up visits, direct measures of adherence were not performed. Details regarding TB diagnosis were not available, and given limited rapid TB diagnostics at the time, there may have been either over-ascertainment or under-ascertainment of TB cases.
In conclusion, this analysis demonstrated that IPT implementation in a population of HIV-positive FSWs in a high TB burden setting was feasible. However, significant losses along the IPT care cascade before IPT initiation underscore the need to identify solutions to improve the efficiency of the screening process. Reducing pre-IPT initiation losses earlier in the cascade could provide greater public health benefit.12 Although ART significantly reduces the risk of TB in PLHIV,37 the risk of active TB remains considerably higher in PLHIV compared with HIV-uninfected individuals even after early ART initiation and immune reconstitution.38,39 Universal ART modeling data suggest ART alone will be insufficient to prevent future HIV-associated TB. Recent data demonstrate that ART and IPT have additive TB prevention and mortality benefits compared with either strategy alone.40,41 Further research is needed regarding long-term follow-up of PLHIV, including key populations, on concurrent ART and IPT under programmatic conditions. Successful TB prevention efforts for PLHIV, including FSWs, will require integration into the HIV care continuum to prevent cascade losses and ensure successful IPT implementation.
The authors thank the study staff at the Women's Health Project and study participants.
1. UNAIDS. Global HIV
Statistics Fact Sheet 2016. 2016. Available at: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf
. Accessed February 15, 2017.
2. World Health Organization. Global Tuberculosis
Report 2016. 2016. Available at: http://www.who.int/tb/publications/global_report/en/
. Accessed February 15, 2017.
3. Martin HL Jr, Nyange PM, Richardson BA, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1998;178:1053–1059.
4. Gilks CF, Godfrey-Faussett P, Batchelor BI, et al. Recent transmission of tuberculosis
in a cohort of HIV
-1-infected female sex workers
in Nairobi, Kenya. AIDS. 1997;11:911–918.
5. World Health Organization. Consolidated Guidelines on HIV
Prevention, Diagnosis, Treatment and Care for Key Populations. 2014. Available at: http://www.who.int/hiv/pub/guidelines/keypopulations/en/
. Accessed February 15, 2017.
6. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection
infected persons. Cochrane Database Syst Rev. 2010:CD000171.
7. World Health Organization. Guidelines for Intensified Tuberculosis
Case-finding and Isoniazid Preventive Therapy
for People Living with HIV
in Resource-constrained Settings. 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf
. Accessed February 1, 2017.
8. Briggs MA, Emerson C, Modi S, et al. Use of isoniazid preventive therapy
prophylaxis among people living with HIV
/AIDS: a review of the literature. J Acquir Immune Defic Syndr. 2015;68 (suppl 3):S297–S305.
9. Uplekar M, Weil D, Lonnroth K, et al. WHO's new end TB strategy. Lancet. 2015;385:1799–1801.
10. World Health Organization. Guidelines on the Management of Latent Tuberculosis Infection
. 2015. Available at: http://www.who.int/tb/publications/latent-tuberculosis-infection/en/
. Accessed February 1, 2017.
11. Kay ES, Batey DS, Mugavero MJ. The HIV
treatment cascade and care continuum: updates, goals, and recommendations for the future. AIDS Res Ther. 2016;13:35.
12. Alsdurf H, Hill PC, Matteelli A, et al. The cascade of care in diagnosis and treatment of latent tuberculosis infection
: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16:1269–1278.
13. Adams LV, Talbot EA, Odato K, et al. Interventions to improve delivery of isoniazid preventive therapy
: an overview of systematic reviews. BMC Infect Dis. 2014;14:281.
14. Cobelens F, van Kampen S, Ochodo E, et al. Research on implementation of interventions in tuberculosis
control in low- and middle-income countries: a systematic review. PLoS Med. 2012;9:e1001358.
15. Daly R, Khatib N, Larkins A, et al. Testing for latent tuberculosis infection
using interferon gamma release assays in commercial sex workers at an outreach clinic in Birmingham. Int J STD AIDS. 2016;27:676–679.
16. Chiang SS, Paulus JK, Huang CC, et al. Tuberculosis
screening among Bolivian sex workers and their children. J Epidemiol Glob Health. 2015;5:205–210.
17. Velasquez MG, Laniado-Laborin R, Rodwell TC, et al. Tuberculosis
testing among populations with high HIV
risk in Tijuana, Baja California, Mexico. Rev Panam Salud Publica. 2012;32:30–35.
18. Ngamvithayapong J, Uthaivoravit W, Yanai H, et al. Adherence to tuberculosis
preventive therapy among HIV
-infected persons in Chiang Rai, Thailand. AIDS. 1997;11:107–112.
19. Kenya Ministry of Health National Tuberculosis
; Leprosy and Lung Disease Unit (NTLD). Kenya NTLD Unit Annual Report 2014. 2014. Available at: http://nltp.co.ke/annual-reports/
. Accessed February 15, 2017.
20. Kenyan Ministry of Health, National AIDS and STI Control Program (NASCOP). Guidelines on use of antiretroviral drugs for treating and preventing HIV
infection: a rapid advice. 2014. Available at: http://healthservices.uonbi.ac.ke/sites/default/files/centraladmin/healthservices/Rapid%20Advice%20Booklet%202014%2024%20June%2012%20noon_0.pdf
21. McClelland RS, Richardson BA, Cherutich P, et al. A 15-year study of the impact of community antiretroviral therapy coverage on HIV
incidence in Kenyan female sex workers
. AIDS. 2015;29:2279–2286.
22. McClelland RS, Graham SM, Richardson BA, et al. Treatment with antiretroviral therapy is not associated with increased sexual risk behavior in Kenyan female sex workers
. AIDS. 2010;24:891–897.
23. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis
infection: a meta-analysis of randomized controlled trials. AIDS. 1999;13:501–507.
24. World Health Organization and UNAIDS. Policy Statement on Preventive Therapy against Tuberculosis
in People Living with HIV
. 1998; Available at: http://apps.who.int/iris/bitstream/10665/64509/1/WHO_TB_98.255.pdf
25. Kenyan Ministry of Health DoL, Tuberculosis
and Lung Disease (DLTLD). DLTLD Guidelines on Management of Leprosy and Tuberculosis
. 2009. Available at: http://www.who.int/hiv/pub/guidelines/kenya_tb.pdf
. Accessed February 1, 2017.
26. Kenya National AIDS/STI Control Program (NASCOP). Guidelines for antiretroviral therapy in Kenya. 2011. Available at: http://healthservices.uonbi.ac.ke/sites/default/files/centraladmin/healthservices/Kenya%20Treatment%20Guidelines%202011.pdf
. Accessed February 15, 2017.
27. Horberg MA, Hurley LB, Klein DB, et al. The HIV care cascade
measured over time and by age, sex, and race in a large national integrated care system. AIDS Patient Care STDS. 2015;29:582–590.
28. Shaw S, Amico KR. Antiretroviral therapy adherence enhancing interventions for adolescents and young adults 13-24 Years of age: a review of the evidence base. J Acquir Immune Defic Syndr. 2016;72:387–399.
29. Kim SH, Gerver SM, Fidler S, et al. Adherence to antiretroviral therapy in adolescents living with HIV
: systematic review and meta-analysis. AIDS. 2014;28:1945–1956.
30. Lall P, Lim SH, Khairuddin N, et al. Review: an urgent need for research on factors impacting adherence to and retention in care among HIV
-positive youth and adolescents from key populations. J Int AIDS Soc. 2015;18(2 suppl 1):19393.
32. Mountain E, Mishra S, Vickerman P, et al. Antiretroviral therapy uptake, attrition, adherence and outcomes among HIV
-infected female sex workers
: a systematic review and meta-analysis. PLoS One. 2014;9:e105645.
33. Hirsch-Moverman Y, Daftary A, Franks J, et al. Adherence to treatment for latent tuberculosis infection
: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008;12:1235–1254.
34. Fox GJ, Barry SE, Britton WJ, et al. Contact investigation for tuberculosis
: a systematic review and meta-analysis. Eur Respir J. 2013;41:140–156.
35. Makanjuola T, Taddese HB, Booth A. Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis
amongst people living with HIV
/AIDS: a systematic review of qualitative data. PLoS One. 2014;9:e87166.
36. Lancaster KE, Cernigliaro D, Zulliger R, Fleming PF. HIV
care and treatment experiences among female sex workers
living with HIV
in sub-Saharan Africa: A systematic review. Afr J AIDS Res 2016,15:377–386.
37. Lawn SD, Wood R, De Cock KM, et al. Antiretrovirals and isoniazid preventive therapy
in the prevention of HIV
in settings with limited health-care resources. Lancet Infect Dis. 2010;10:489–498.
38. Gupta A, Wood R, Kaplan R, et al. Tuberculosis
incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One. 2012;7:e34156.
39. Kufa T, Mabuto T, Muchiri E, et al. Incidence of HIV
among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis. PLoS One. 2014;9:e111209.
40. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis
: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682–690.
41. Temprano ANRS Study Group. A trial of early antiretrovirals and isoniazid preventive therapy
in Africa. N Engl J Med. 2015;373:808–822.
42. Badje A, Moh R, Gabillard D, et al. Six-month IPT reduces mortality independent of ART in African adults with high CD4. Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 13–16, 2017; Seattle, WA.